Back

In vitro activity of tigecycline against the multidrug-resistant bacteria isolated from burn patients

Abstract number: 1733_1538

Kurt Azap Ö., Timurkaynak F., Karaman S., Arslan H.

Introduction: Infections in burn patients are usually caused by multidrug-resistant microorganisms. Tigecycline, a derrivative of glycylcyclines, is an effective antibiotic against the resistant strains. The aim of this study is to determine the in vitro activity of tigecycline against the multi-drug resistant bacteria isolated from burn patients.

Materials and Methods: Fourty-five bacteria isolated from 118 patients hospitalised in the burn unit during 2003–3005 were included in the study. Gram-negative bacteria that were resistant to at least two classes of antibiotics among the b-lactam, quinolone, aminoglycoside classes, methicillin-resistant staphylococci, ampicillin-resistant enterococci were studied. Minimal inhibitory concentration values of tigecycline against these bacteria were tested by E test strips. Susceptibility breakpoints were determined according to the previous studies; ≤0.25 mg/L for enterococci, ≤0.5 mg/L for staphylococci and ≤2 mg/L for Acinetobacter baumannii.

Results: Fourty-seven percent of the materials were obtained from wound, 31% from tissue specimens, 27% from blood and 3% from catheters. MIC50 and MIC90 values were shown in the Table.

MIC values of tigecycline against the bacteria isolated from burn patients

Bacteria (n)MIC (mg/L)
RangeMIC50MIC90 
Enterococcus spp.0.032–10.1250.25
Methicillin-resistant S. aureus0.19–20.251.5
Acinetobacter baumannii0.50–212

Conclusion: Susceptibility rates were found to be 94.2%, 85.5%, 100% for MRSA, enterococci, A. baumannii respectively. These results are in accordance with the other studies. In conclusion, tigecycline seems to be a good alternative for the difficult-to-treat infections in burn patients.

Session Details

Date: 31/03/2007
Time: 00:00-00:00
Session name: European Society of Clinical Microbiology and Infectious Diseases
Subject:
Location: ICC, Munich, Germany
Presentation type:
Back to top